Genmab — November 2018
-
Ang. 16:03. Fra andet studie: "The toxicity profile was mild and reversible. No secondary carcinoma was observed, and 24 months after the last dose of ATRA/ATO, patients had urine arsenic concentrations well below the safety limit. These results demonstrate the high efficacy and minimal toxicity of ATRA/ATO treatment for newly diagnosed APL in long-term follow-up"
-
-
God morgen.
-
Mon denne kunne være en kommende combi partner med Dara i NSCLC på sigt. ? https://www.fiercebiotech.com/biotech/janssen-taps-south-korea-s-yuhan-for-tagrisso-rival?mkt_tok=eyJpIjoiWTJZME5qQTJaakV6TXprNCIsInQiOiJEZEs0VEFMamdoSm5ORmpBXC9wK0lVeitncU5JUDY1Unp0K2dnTEFyUHZxeFptdVdBQk50XC8zaERWZzJBQUlYbTN5VHU0TVlXQ2NhWGprblFsWEtzN3hiZ3BJZTl6ODhoSVpiT1dCTzZcLzRma1NtQkZIU01NZ3ZVVDVGbXltYWt3ZSJ9&mrkid=41140432
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind